A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease is a research paper published in Clinical Kidney Journal (2020). On theSindex it has a DataRank of 0. It has been cited 24 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
US Food and Drug Administration
Grant: RO1 FD004826
Clinical Translational Science Award
Grant: UL1TR002529-01
Diabetes and Digestive and Kidney Diseases
Grant: P30DK090728
NIH
Grant: AR072581
NIH
Grant: DK110871
NIH
Grant: ULTR002529-01
Department of Defense Peer Reviewed Medical Research Program
Grant: W81XWH-16-PRMRP-IIRA
NIH
Grant: NIH-K23DK102824
NIDDK NIH HHS
Grant: R01 DK110871
NIAMS NIH HHS
Grant: P30 AR072581
NIDDK NIH HHS
Grant: K23 DK102824
FDA HHS
Grant: R01 FD004826
NCATS NIH HHS
Grant: UL1 TR002529
National Institutes of Health
Grant: 5K23DK102824-04
Longitudinal Assessment of Skeletal Muscle Physiology in Dialysis Patients
National Institutes of Health
Grant: 5R01DK110871-02
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.
National Institutes of Health
Grant: 5UL1TR002529-02
Indiana Clinical and Translational Sciences Institute
National Institutes of Health
Grant: 1P30AR072581-01
Indiana Core Center for Clinical Research in Musculoskeletal Health
National Institutes of Health
Grant: 1P30DK090728-01
Mayo Translational PKD Center (MTPC)
National Institues of Health
Polycystic Kidney Disease Foundation
NIH
Mayo Clinic Robert M. and Billie Kelley Pirnie Translational PKD Center
FWCI
2.56
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals